Pharmaceutical sponsor
Nanjing Chia-tai Tianqing Pharmaceutical Clinical Trials
Studies where Nanjing Chia-tai Tianqing Pharmaceutical is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 10Acromegaly
A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers
This is a phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of single oral doses of NTQ6179 tablets in healthy…
- Trial name
- NCT07909837
- Testing
- NTQ6179
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Thyroid Eye Disease
An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)
Multicentre, Phase Ib/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of NTB003 in Participants with Thyroid Eye Disease
- Trial name
- NCT07462130
- Testing
- NTB003
- Volunteers
- 74 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer
NTQ1062-301 is a randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of the small-molecule AKT inhibitor NTQ1062 combined with fulvestrant versus placebo combined with…
- Trial name
- NCT07393321
- Testing
- NTQ1062+Fulvestrant
- Volunteers
- 210 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
TED
Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants
This study is a randomized, double-blind, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic characteristics of NTB003 injection in healthy volunteers.
- Trial name
- NCT07182552
- Testing
- NTB003
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Paroxysmal Nocturnal Hemoglobinuria
A Long-term Efficacy and Safety of NTQ5082 Capsules
NTQ5082 capsules are a small molecule CFB inhibitor. This study is a multicenter, open-label study evaluating the long-term efficacy and safety of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal…
- Trial name
- NCT07177872
- Testing
- NTQ5082 capsules 200 mg
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Paroxysmal Nocturnal Hemoglobinuria
A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients
NTQ5082 capsules are a small molecule CFB inhibitor. This study is a multicenter, randomized, open-label, active-controlled Phase III clinical trial designed to evaluate the efficacy and safety of NTQ5082 capsules in the…
- Trial name
- NCT07177859
- Testing
- NTQ5082 capsules 200 mg, Eculizumab Injection
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Primary IgA Nephropathy
Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy
NTQ5082 is a small molecule inhibitor of complement factor B (CFB) that inhibits the enzymatic activity of CFB, thereby blocking the alternative pathway of the complement activation cascade.
- Trial name
- NCT06982040
- Testing
- NTQ5082 capsules 100 mg, NTQ5082 capsules 200 mg, NTQ5082 capsules 300 mg
- Volunteers
- 80 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Acute Normovolemic Hemodilution
Clinical Study on the Effectiveness and Safety of Succinylated Gelatin Injection
The succinylated gelatin injection (specification: 500 mL: 20 g) developed and produced by Nanjing Chia-tai Tianqing Pharmaceutical..
- Trial name
- NCT06977763
- Testing
- succinylated gelatin injection 1, succinylated gelatin injection
- Volunteers
- 104 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Acute Normovolemic Hemodilution
Clinical Study on the Effectiveness and Safety of Succinylated Gelatin Electrolyte Sodium Acetate Injection
The succinylated gelatin electrolyte sodium acetate injection (specification: 500 mL: 20 g) developed and produced by Nanjing Chia-tai Tianqing Pharmaceutical.
- Trial name
- NCT06977750
- Testing
- succinylated gelatin electrolyte sodium acetate injection 1, succinylated gelatin electrolyte sodium acetate injection
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Chronic Insomnia
A Study of Ramelteon in Chinese Patients With Chronic Insomnia
The purpose of this study is to assess the efficacy and safety of Ramelteon in chinese patients with chronic insomnia. Efficacy will be evaluated on objective and subjective sleep parameters.
- Trial name
- NCT06512363
- Testing
- Ramelteon
- Volunteers
- 280 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical